MX2020005364A - Anticuerpos anti-ox40 y usos de los mismos. - Google Patents

Anticuerpos anti-ox40 y usos de los mismos.

Info

Publication number
MX2020005364A
MX2020005364A MX2020005364A MX2020005364A MX2020005364A MX 2020005364 A MX2020005364 A MX 2020005364A MX 2020005364 A MX2020005364 A MX 2020005364A MX 2020005364 A MX2020005364 A MX 2020005364A MX 2020005364 A MX2020005364 A MX 2020005364A
Authority
MX
Mexico
Prior art keywords
antibodies
tnfrsf4
antigen
disclosure provides
binding fragments
Prior art date
Application number
MX2020005364A
Other languages
English (en)
Inventor
Fang Yang
Yi Yang
Yanan Guo
Xiaodong Cheng
Yunyun Chen
Jingshu Xie
Chunyan Dong
Chengyuan Lu
Yuelei Shen
Jian Ni
Original Assignee
Eucure Beijing Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eucure Beijing Biopharma Co Ltd filed Critical Eucure Beijing Biopharma Co Ltd
Publication of MX2020005364A publication Critical patent/MX2020005364A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta descripción se refiere a anticuerpos anti-OX40 (Miembro 4 de la Superfamilia del Receptor TNF, o TNFRSF4), fragmentos de unión a antígeno, y usos de los mismos.
MX2020005364A 2017-11-24 2017-11-24 Anticuerpos anti-ox40 y usos de los mismos. MX2020005364A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/112832 WO2019100320A1 (en) 2017-11-24 2017-11-24 Anti-ox40 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2020005364A true MX2020005364A (es) 2020-08-13

Family

ID=66630359

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005364A MX2020005364A (es) 2017-11-24 2017-11-24 Anticuerpos anti-ox40 y usos de los mismos.

Country Status (12)

Country Link
US (2) US10934365B2 (es)
EP (1) EP3713958A4 (es)
JP (2) JP7479281B2 (es)
KR (2) KR20240023192A (es)
CN (1) CN112292397B (es)
AU (1) AU2017440393A1 (es)
BR (1) BR112020010137A2 (es)
CA (1) CA3084394A1 (es)
IL (1) IL274502A (es)
MX (1) MX2020005364A (es)
SG (1) SG11202003443TA (es)
WO (1) WO2019100320A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112292397B (zh) * 2017-11-24 2023-01-31 祐和医药科技(北京)有限公司 抗ox40抗体及其用途
WO2021098851A1 (en) * 2019-11-20 2021-05-27 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4/ox40 bispecific antibodies and uses thereof
KR20220103709A (ko) * 2019-11-21 2022-07-22 베이진 엘티디 항-tigit 항체와의 병용물 형태로 항-ox40 항체를 사용하는 암 치료의 방법
TW202144423A (zh) * 2020-04-17 2021-12-01 大陸商和記黃埔醫藥（上海）有限公司 抗ｏｘ４０抗體及其用途
US20230404642A1 (en) * 2022-06-01 2023-12-21 Syncromune, Inc. Method for the treatment of cancer via tumor cell lysis and intratumoral administration of combinations of immunotherapeutic ingredients

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
EP0845537A1 (en) 1989-08-18 1998-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
WO2003059245A2 (en) * 2001-12-18 2003-07-24 J & J Research Pty Ltd Method of treating asthma
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
KR20080080639A (ko) 2005-12-16 2008-09-04 제넨테크, 인크. 항-ｏｘ40ｌ 항체 및 그의 사용 방법
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
RU2010129045A (ru) * 2007-12-14 2012-01-20 Бристоль-Мейерз Сквибб Компани (US) Связывающие молекулы к рецептору ох40 человека
CN105229032A (zh) * 2013-03-18 2016-01-06 比奥塞罗克斯产品公司 人源化抗cd134(ox40)抗体及其应用
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
SG11201608106PA (en) 2014-03-31 2016-10-28 Genentech Inc Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
MY188049A (en) 2015-05-29 2021-11-12 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
EP3363816A4 (en) * 2015-10-15 2019-10-09 Dingfu Biotarget Co., Ltd. ANTI-OX40 ANTIBODIES AND USES THEREOF
US20200079862A1 (en) * 2015-12-03 2020-03-12 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
WO2018041119A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ox40
KR102543719B1 (ko) * 2017-09-21 2023-06-16 유큐(베이징) 바이오파마 코., 엘티디 항―ｃｔｌａ４ 항체 및 그의 용도
CN112292397B (zh) 2017-11-24 2023-01-31 祐和医药科技(北京)有限公司 抗ox40抗体及其用途
IL276675B2 (en) * 2018-02-23 2023-10-01 Eucure Beijing Biopharma Co Ltd Anti-PD-1 antibodies and uses thereof
WO2021098851A1 (en) * 2019-11-20 2021-05-27 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4/ox40 bispecific antibodies and uses thereof
WO2021113625A1 (en) * 2019-12-06 2021-06-10 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor

Also Published As

Publication number Publication date
JP2022179623A (ja) 2022-12-02
EP3713958A1 (en) 2020-09-30
RU2020116668A (ru) 2021-12-27
CA3084394A1 (en) 2019-05-31
KR20240023192A (ko) 2024-02-20
US20200332018A1 (en) 2020-10-22
BR112020010137A2 (pt) 2020-10-13
JP7479281B2 (ja) 2024-05-08
WO2019100320A1 (en) 2019-05-31
IL274502A (en) 2020-06-30
EP3713958A4 (en) 2021-11-03
SG11202003443TA (en) 2020-05-28
JP2021503911A (ja) 2021-02-15
KR102634374B1 (ko) 2024-02-06
CN112292397A (zh) 2021-01-29
US20210206866A1 (en) 2021-07-08
KR20200088810A (ko) 2020-07-23
RU2020116668A3 (es) 2021-12-27
CN112292397B (zh) 2023-01-31
US10934365B2 (en) 2021-03-02
US11999790B2 (en) 2024-06-04
AU2017440393A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
MX2020005364A (es) Anticuerpos anti-ox40 y usos de los mismos.
PH12018501554A1 (en) Ror1 antibody compositions and related methods
HK1257518A1 (zh) 針對人白介素-2的免疫刺激性人源化單克隆抗體及其融合蛋白
WO2017123673A3 (en) Multivalent and multispecific ox40-binding fusion proteins
WO2017123650A3 (en) Multivalent and multispecific 41bb-binding fusion proteins
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
WO2016191643A3 (en) Tigit-binding agents and uses thereof
MD4795C1 (ro) Anticorp monoclonal anti-CTLA4 sau fragment de legare a acestuia la antigen, compoziţie farmaceutică şi utilizarea lor
MX2022014695A (es) Anticuerpos anti-gitr y sus usos.
MX2019015348A (es) Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1).
NZ741067A (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
MX2020003093A (es) Anticuerpos anti-cd19 novedosos.
EP3705494A3 (en) Antibodies against frizzled proteins and methods of use thereof
MX2020002241A (es) Anticuerpos anti-tm4sf y métodos de uso de los mismos.
MX2021000688A (es) Anticuerpos anti-cd40 y usos de los mismos.
MX2021002750A (es) Anticuerpos anti-tnfrsf9 y usos de los mismos.
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
IL291545A (en) Antibodies against ctla4, antibody fragments, their immunoconjugates and their uses
IL276746A (en) Kir3dl3 as hhla2 receptor, anti-hhla2 antibodies and their uses
MX2018013072A (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
PH12018502275A1 (en) Interferon beta antibodies and uses thereof
PH12020550890A1 (en) Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
WO2019028182A3 (en) TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40)
PH12019502694A1 (en) Anti-trkb antibodies
MX2022007959A (es) Nuevos anticuerpos anti-fgfr2b.